Roman Willi
Project Leader


Roman Willi leads all scientific and business development activities related to the Nogo-A therapy. He is also acting as the founding CEO and CSO of the University of Zurich spin-off NovaGo Therapeutics AG. Prior to his current assignments, Roman Willi held a global role within Neuroscience Product Development at Roche, where he was the Lead Clinical Scientist for two large phase III clinical trials in Multiple Sclerosis. Prior to that, he was involved in preclinical research projects within Roche’s Neuroscience Discovery Department. He received his Ph.D. from ETH Zurich, where he studied with Martin Schwab at the Brain Research Institute.


Michael Maurer
Senior Scientist


Michael Maurer is part of the Wyss Zurich Novago team since January 2016. Originally coming from the pharmaceutical industry and being educated as chemical laboratory technician, he later received his M.Sc. in Biotechnology from ETH Zurich and his Ph.D. in Immunology from the University of Zurich. As Senior Scientist in the Schwab laboratory, his research focuses on Nogo-A antigens and anti-Nogo-A antibodies. Within the Wyss Zurich Novago project, he serves as consultant for all antibody-related tasks and questions.

Tel: +41 44 635 32 13

Christina Sina
Project Manager


Christina Sina joined Wyss Zurich in January 2016. She holds a Ph.D. in Immunology from the University of Zurich and worked in a PR agency for life science and health care communication. She is the scientific coordinator of Martin Schwab and supports the translation of his basic Nogo-A research into clinical application of the anti-Nogo-A antibody therapy. She functions as project manager and supports business-related activities.

Tel: +41 44 635 32 62